BiotechTube

Crizotinib + Enzalutamide

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Castration-resistant Prostate Cancer

Conditions

Castration-resistant Prostate Cancer

Trial Timeline

Aug 1, 2014 → Jan 3, 2022

NCT ID
NCT02207504

About Crizotinib + Enzalutamide

Crizotinib + Enzalutamide is a phase 1 stage product being developed by Astellas Pharma for Castration-resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02207504. Target conditions include Castration-resistant Prostate Cancer.

What happened to similar drugs?

4 of 20 similar drugs in Castration-resistant Prostate Cancer were approved

Approved (4) Terminated (1) Active (15)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅olaparib + enzalutamide + abiraterone acetate + PrednisoneAstraZenecaApproved
✅Darolutamide (Nubeqa, BAY1841788)BayerApproved
🔄Enzalutamide + PlaceboAstellas PharmaPhase 3
🔄Enzalutamide + PlaceboAstellas PharmaPhase 3
🔄[Lu-177]-PNT2002 + Abiraterone + EnzalutamideEli LillyPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02207504Phase 1Completed

Competing Products

20 competing products in Castration-resistant Prostate Cancer

See all competitors
ProductCompanyStageHype Score
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue MedicationDaiichi SankyoPhase 1/2
39
Valemetostat + DarolutamideDaiichi SankyoPhase 1
36
EnzalutamideAstellas PharmaPhase 2
35
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
35
EnzalutamideAstellas PharmaPhase 2
35
Lu-PSMA + EnzalutamideAstellas PharmaPhase 2
31
EnzalutamideAstellas PharmaApproved
43
enzalutamideAstellas PharmaPre-clinical
26
Enzalutamide + FlutamideAstellas PharmaPhase 2
35
Enzalutamide + Abiraterone acetateAstellas PharmaPre-clinical
26
EnzalutamideAstellas PharmaApproved
43
EnzalutamideAstellas PharmaPhase 2
35
MDV3100Astellas PharmaPre-clinical
26
Enzalutamide + PlaceboAstellas PharmaPhase 3
40
ZEN003694 + EnzalutamideAstellas PharmaPhase 2
42
Enfortumab vedotinAstellas PharmaPhase 2
39
EnzalutamideAstellas PharmaPhase 2
27
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + PlaceboAstellas PharmaPhase 3
40